SALT LAKE CITY, UTAH / ACCESS Newswire / August 26, 2025 / Kindly MD, Inc. (NASDAQ:NAKA) ("KindlyMD" or the "Company"), a provider of integrated healthcare services and a Bitcoin treasury vehicle, today announced that it has filed a shelf registration statement and prospectus supplement with the U.S. Securities and Exchange Commission ("SEC") establishing an at-the-market equity offering program (the "ATM Program") under which it may issue and sell shares of its common stock, $0.001 par value per share (the "NAKA Stock"), having an aggregate offering price of up to $5 billion (the "Offered Shares"). KindlyMD intends to use the net proceeds from the ATM Program for general corporate purposes, which include, among other things, pursuit of a Bitcoin Treasury Strategy, in alignment with the Company's Bitcoin treasury strategy following its merger with Nakamoto Holdings Inc. ("Nakamoto" and together with KindlyMD, the "combined company"), working capital, funding of acquisitions of businesses, assets or technologies, capital expenditures, and/or investing in existing and future projects.
"The launch of the ATM Program represents a pivotal step in our long-term capital strategy," said David Bailey, Chief Executive Officer and Chairman of KindlyMD. "Following the successful completion of our merger between KindlyMD and Nakamoto just two weeks ago and our initial purchase of 5,744 Bitcoin, this initiative is the natural next phase of our growth plan. We intend to deploy the ATM Program thoughtfully and methodically, using it as a flexible tool to strengthen our balance sheet, seize market opportunities, and deliver accretive value for our shareholders."
Pursuant to the terms of the sales agreement, dated August 26, 2025 (the "Sales Agreement"), among KindlyMD and TD Securities; Cantor; B. Riley Securities, Inc; Benchmark, a StoneX Company; Canaccord Genuity; Cohen & Company Capital Markets; Craig-Hallum; Needham & Company; and Yorkville Securities (the "Sales Agents"), sales of the Offered Shares, if any, of the NAKA Stock under the ATM Program will be made by any method permitted by law deemed to be an "at the market offering" as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, including sales made directly on or through the Nasdaq Global Market or any other existing trading market for the NAKA Stock. The timing and amount of any such sales will be determined by a variety of factors considered by the Company. Sales may be made at market prices prevailing at the time of a sale or at prices related to prevailing market prices. As a result, sales prices may vary.
The ATM Program is being made pursuant to a prospectus supplement dated August 26, 2025 to the Company's base prospectus included in its registration statement on Form S-3 (File No. 333-289868) filed with the SEC on August 26, 2025, which automatically became effective upon filing. Before making an investment in the Offered Shares, potential investors should read the prospectus supplement and the accompanying base prospectus for more information about KindlyMD and the ATM Program. Copies of the prospectus supplement, the accompanying base prospectus and the Sales Agreement are available on the SEC's website at www.sec.gov. Potential investors can request copies of the prospectus supplement and the accompanying base prospectus from the Sales Agents by contacting: TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, by telephone at (833) 297-2926 or by email at TD.ECM_Prospectus@tdsecurities.com; Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, New York, New York 10022; or by email at prospectus@cantor.com; B. Riley Securities, 1300 17th Street North, Suite 1300, Arlington, VA 22209, Attention: Prospectus Department, by telephone at (703) 312-9580 or by email at prospectuses@brileysecurities.com; The Benchmark Company, LLC, 150 East 58th Street, 17th Floor, New York, NY 10155, Attention: Prospectus Department, or by email at prospectus@benchmarkcompany.com; Canaccord Genuity LLC, Attention: Syndicate Department, One Post Office Square, Suite 3000, Boston, MA 02109, or by email at prospectus@cgf.com; Cohen and Company Capital Markets, a division of Cohen & Company Securities, LLC, 3 Columbus Circle, 24th Floor, New York, New York 10019, Attention: Prospectus Department, or by email at capitalmarkets@cohencm.com; Craig-Hallum Capital Group LLC, Attention: Equity Capital Markets, 323 N. Washington Ave., Suite 300, Minneapolis, MN 55401, by telephone at (612) 334-6300 or by email at prospectus@chlm; Needham & Company, LLC, 250 Park Avenue, 10th Floor, New York, NY 10177, Attn: Prospectus Department, prospectus@needhamco.com or by telephone at (800) 903-3268; and Yorkville Securities, LLC, 1012 Springfield Avenue, Mountainside, New Jersey 07092, Email: legal@yorkvillesecurities.com, Attention: General Counsel.
This press release is for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About KindlyMD
KindlyMD® is a patient-first and healthcare data company redefining value-based care and patient-centered medical services. Formed in 2019, Kindly MD leverages data analysis to deliver evidence-based, personalized solutions in order to reduce opioid use, improve health outcomes faster, and provide value based, algorithmic guidance on the use of alternative medicine in healthcare. In August 2025, KindlyMD completed its merger with Nakamoto Holdings Inc., a Bitcoin-native holding company. This strategic formed a public Bitcoin treasury strategy that unites KindlyMD's healthcare expertise with Nakamoto's vision of integrating Bitcoin into global capital markets, creating a diversified entity focused on both healthcare innovation and Bitcoin treasury management.
Forward-Looking Statements
This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by the use of words such as "should," "may," "intends," "anticipates," "believes," "estimates," "projects," "forecasts," "expects," "plans," and "proposes." These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, and include, for example, our expected use of proceeds from the ATM Program. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading "Risk Factors" in KindlyMD, Inc.'s Annual Report on Form 10-K for the fiscal year ended December 31, 2024. KindlyMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release.
Contacts
Investor Relations:
Valter Pinto, Managing Director
KCSA Strategic Communications
(212) 896-1254
KindlyMD@KCSA.com
Media:
Carissa Felger / Sam Cohen
Gasthalter & Co.
(212) 257-4170
Nakamoto@gasthalter.com
SOURCE: KindlyMD, Inc
View the original press release on ACCESS Newswire